טוען...
Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis
Abstract Background Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcomes of RTX in adults with FSGS and MCD. M...
שמור ב:
Main Authors: | , , , |
---|---|
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
BMC
2020-04-01
|
סדרה: | BMC Nephrology |
נושאים: | |
גישה מקוונת: | http://link.springer.com/article/10.1186/s12882-020-01797-7 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|